Current and future use of intravenous thrombolysis for acute ischemic stroke

Lucas Elijovich, Ji Y. Chong

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Stroke is a common and disabling condition. Intravenous tissue plasminogen activator (tPA) administered within 3 h of symptom onset is the standard therapy for eligible patients with acute ischemic stroke. Unfortunately, because of the time limitation, very few patients with ischemic stroke actually receive this treatment. In order to increase the number of patients who may benefit from acute treatment, recent research has focused on expanding the time window for thrombolysis and improving its efficacy to ultimately improve patient outcome.

Original languageEnglish (US)
Pages (from-to)316-321
Number of pages6
JournalCurrent atherosclerosis reports
Volume12
Issue number5
DOIs
StatePublished - Sep 1 2010
Externally publishedYes

Fingerprint

Stroke
Tissue Plasminogen Activator
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Current and future use of intravenous thrombolysis for acute ischemic stroke. / Elijovich, Lucas; Chong, Ji Y.

In: Current atherosclerosis reports, Vol. 12, No. 5, 01.09.2010, p. 316-321.

Research output: Contribution to journalReview article

@article{451060a8730a49de96f38699987f807c,
title = "Current and future use of intravenous thrombolysis for acute ischemic stroke",
abstract = "Stroke is a common and disabling condition. Intravenous tissue plasminogen activator (tPA) administered within 3 h of symptom onset is the standard therapy for eligible patients with acute ischemic stroke. Unfortunately, because of the time limitation, very few patients with ischemic stroke actually receive this treatment. In order to increase the number of patients who may benefit from acute treatment, recent research has focused on expanding the time window for thrombolysis and improving its efficacy to ultimately improve patient outcome.",
author = "Lucas Elijovich and Chong, {Ji Y.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1007/s11883-010-0121-8",
language = "English (US)",
volume = "12",
pages = "316--321",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Current and future use of intravenous thrombolysis for acute ischemic stroke

AU - Elijovich, Lucas

AU - Chong, Ji Y.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Stroke is a common and disabling condition. Intravenous tissue plasminogen activator (tPA) administered within 3 h of symptom onset is the standard therapy for eligible patients with acute ischemic stroke. Unfortunately, because of the time limitation, very few patients with ischemic stroke actually receive this treatment. In order to increase the number of patients who may benefit from acute treatment, recent research has focused on expanding the time window for thrombolysis and improving its efficacy to ultimately improve patient outcome.

AB - Stroke is a common and disabling condition. Intravenous tissue plasminogen activator (tPA) administered within 3 h of symptom onset is the standard therapy for eligible patients with acute ischemic stroke. Unfortunately, because of the time limitation, very few patients with ischemic stroke actually receive this treatment. In order to increase the number of patients who may benefit from acute treatment, recent research has focused on expanding the time window for thrombolysis and improving its efficacy to ultimately improve patient outcome.

UR - http://www.scopus.com/inward/record.url?scp=77956257659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956257659&partnerID=8YFLogxK

U2 - 10.1007/s11883-010-0121-8

DO - 10.1007/s11883-010-0121-8

M3 - Review article

VL - 12

SP - 316

EP - 321

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 5

ER -